本文選題：HBV + DNA��； 參考：《吉林大學(xué)》2006年碩士論文

【摘要】：乙型肝炎病毒(HBV)感染是嚴重危害人類健康的傳染病之一,基因重組乙肝疫苗是目前為止預(yù)防乙肝病毒感染的有力手段。然而在接種乙肝疫苗的健康人群中約有14%的人表現(xiàn)為對疫苗抗原的無應(yīng)答或弱應(yīng)答,不能產(chǎn)生保護力水平的抗體,因此,研制新型乙肝疫苗及改進現(xiàn)有乙肝疫苗的免疫活性成為目前急需解決的問題。有關(guān)研究結(jié)果表明,乙肝病毒DNA疫苗可在免疫動物體內(nèi)誘導(dǎo)出持續(xù)的體液免疫和細胞免疫反應(yīng),并能打破機體對HBV的免疫耐受,可兼作預(yù)防性和治療性疫苗,是未來新型疫苗的發(fā)展方向之一。 本研究將微小病毒內(nèi)部核糖體進入位點(IRES)基因克隆到核酸疫苗載體pVAXⅠ多克隆位點處,再將乙肝病毒表面抗原(HBsAg)基因和粒細胞-巨噬細胞集落刺激因子(GM-CSF)基因依次克隆到IRES的上、下游多克隆位點處,構(gòu)建出核酸疫苗雙表達載體pHIG。 用雙表達質(zhì)粒pHIG免疫BaLB/C小鼠,同時設(shè)置陰性對照組注射pVAXⅠ空質(zhì)粒,并分別于第2、4周后加強免疫各1次。 結(jié)果顯示,試驗組在免疫1周時開始有HBsAb的產(chǎn)生,陰性對照組未測到HBsAb。含有乙肝病毒HbsAg基因與GM-CSF基因的雙表達質(zhì)粒能引起小鼠特異性體液免疫應(yīng)答并可使免疫效果提高1倍。
[Abstract]:Hepatitis B virus (HBV) infection is one of the most serious infectious diseases, and recombinant hepatitis B vaccine is a powerful method to prevent hepatitis B virus infection. However, about 14% of the healthy people who were vaccinated with hepatitis B vaccine showed no or weak response to the vaccine antigen and could not produce antibodies at the protective level. It is urgent to develop new hepatitis B vaccine and improve the immune activity of existing hepatitis B vaccine. The results show that HBV DNA vaccine can induce sustained humoral and cellular immune responses in immunized animals, break the immune tolerance to HBV, and can be used as both prophylactic and therapeutic vaccines. It is one of the development directions of the new vaccine in the future. In this study, the internal ribosome entry site (IRES) gene of parvovirus was cloned to the polyclonal site of nucleic acid vaccine vector pVAX 鈪，

本文編號：2042330